An introduction to Particle Works, its technology and product roadmap
Thank you for your interest in our webinar. In this session we talked about how automated microfluidics have significant potential for removing the common roadblocks to progress in nanoparticle-based therapies, such as time delays and financial limitations, contributing to advances in the clinical development of nanomedicines.
The webinar was hosted by Lee Jeffries, Managing Director of Particle Works; Gareth Bolitho, Commercial Manager; and Ben Knappett, Head of Science and Applications.
Recently spun out of Dolomite Microfluidics, Particle Works designs and manufactures state-of-the-art automated nanoparticle synthesis platforms for drug delivery solutions. Our technology is used in a wide range of applications, including the production of nanoparticle-based vaccines, medicines, and therapeutics. We have been at the forefront of this rapidly changing science, listening and adapting as our customers’ needs have evolved. Our platforms enable scientists to formulate particles faster, ensuring they are ready for their next breakthrough and the scale up of discoveries.
During the webinar we discussed:
- Why interest in lipid nanoparticles (LNPs) has grown significantly in the last decade and the benefits they offer for an effective drug delivery process.
- Microfluidic technology for the production of LNPs – key challenges and available solutions.
- Particle Works as a dedicated drug development company.